Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, 1015 Lausanne, Switzerland.
Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, 1015 Lausanne, Switzerland
Cold Spring Harb Perspect Med. 2024 Jun 3;14(6):a041380. doi: 10.1101/cshperspect.a041380.
In the last decade, organoid technology has become a cornerstone in cancer research. Organoids are long-term primary cell cultures, usually of epithelial origin, grown in a three-dimensional (3D) protein matrix and a fully defined medium. Organoids can be derived from many organs and cancer types and sites, encompassing both murine and human tissues. Importantly, they can be established from various stages during tumor evolution and recapitulate with high accuracy patient genomics and phenotypes in vitro, offering a platform for personalized medicine. Additionally, organoids are remarkably amendable for experimental manipulation. Taken together, these features make organoids a powerful tool with applications in basic cancer research and personalized medicine. Here, we will discuss the origins of organoid culture, applications in cancer research, and how cancer organoids can synergize with other models of cancer to drive basic discoveries as well as to translate these toward clinical solutions.
在过去的十年中,类器官技术已成为癌症研究的基石。类器官是长期的原代细胞培养物,通常来源于上皮组织,在三维(3D)蛋白基质和完全定义的培养基中生长。类器官可以源自多种器官和癌症类型及部位,包括鼠类和人类组织。重要的是,它们可以从肿瘤进化的各个阶段建立,并在体外高度准确地再现患者的基因组和表型,为个性化医疗提供了一个平台。此外,类器官非常适合进行实验操作。综上所述,这些特点使类器官成为一种强大的工具,可应用于基础癌症研究和个性化医疗。在这里,我们将讨论类器官培养的起源、在癌症研究中的应用,以及癌症类器官如何与其他癌症模型协同作用,推动基础发现,并将这些发现转化为临床解决方案。